drugset / Trial / NCT05380986
Camrelizumab Combined With Apatinib Mesylate
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors
Timeline
- Start
- 2022-05-20
- Primary completion
- 2024-05-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Other |
| Subject | Rivoceranib | Small molecule | — | — |